Developing Dual-State Emission Berberine Derivatives as Theranostic Agents by Reducing Nonradiative Transition Pathways
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Fuquan Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Children's Hospital; Affiliated Shenzhen Children's Hospital of Shantou University Medical College, Shenzhen, Guangdong 518038, China. Hauptthemen laut MEDLINE: Berberine, Anti-Bacterial Agents, Photosensitizing Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Nankai University, Science, Technology and Innovation Commission of Shenzhen Municipality.
Abstract (Originalsprache)
Berberine, an antibacterial natural product, shows promise as a theranostic agent. However, berberine exhibits moderate antibacterial efficacy and limited water solubility, restricting its clinical application. In this study, we discovered that a berberine derivative B-12 exhibits dual-state emission (DSE) characteristics, and its photodynamic antibacterial activity is significantly higher than that of berberine and methylene blue. The mechanistic studies suggested that substitution with a single methoxy group at the C-3 position reduces the intramolecular electron transfer and increases the energy gap between singlet and triplet excited states, which reduces nonradiative transition pathways and improves the fluorescence quantum yield. The C-3 methoxy group also contributes to higher ROS production due to the longer lifetime of the excited state. Through bioimaging, B-12 was able to discriminate between Gram-positive and Gram-negative bacteria. Notably, this study offers valuable insights for designing photodynamic and DSE-active berberine derivatives, highlighting the potential of these derivatives as theranostic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shenzhen Children's Hospital; Affiliated Shenzhen Children's Hospital of Shantou University Medical College, Shenzhen, Guangdong 518038, China.
- Institute of Biomedical & Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
- Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
- Xiamen Key Laboratory for Tumor Metastasis, Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China.
- State Key Laboratory of Physical Chemistry of Solid Surfaces, Key Laboratory of Chemical Biology of Fujian Province, iCHEM, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, China.
- Publicity Department, Affiliated Children's Hospital, Xi'an Jiaotong University, Xi'an 710003, China.
ORCID-Profile: Fuquan Xie, Tianhui Hu, Yandong Zhang
Förderung
- Guangdong Provincial Department of Science and Technology
- Nankai University
- Science, Technology and Innovation Commission of Shenzhen Municipality
- National Natural Science Foundation of China
Zitieren
APA
Xie, F., Xu, B., Chen, P., Qin, Y., Pei, W., Li, J., Hu, T., Gao, Q., Chen, S., Zhang, Y., Li, D., & Xie, Z. (2025). Developing Dual-State Emission Berberine Derivatives as Theranostic Agents by Reducing Nonradiative Transition Pathways. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00191
Vancouver
Xie F, Xu B, Chen P, Qin Y, Pei W, Li J, et al. Developing Dual-State Emission Berberine Derivatives as Theranostic Agents by Reducing Nonradiative Transition Pathways. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00191
BibTeX
@article{Xie2025,
author = {Xie, Fuquan and Xu, Beibei and Chen, Peng and Qin, Yushan and Pei, Wenbin and Li, Jiangquan and Hu, Tianhui and Gao, Qi and Chen, Siying and Zhang, Yandong and Li, Defa and Xie, Zhongjian},
title = {Developing Dual-State Emission Berberine Derivatives as Theranostic Agents by Reducing Nonradiative Transition Pathways},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00191}
}
EUVIMED